SCHEMBL4411051

SCHEMBL4411051

CC(C)(C)OC(=O)N1CCN2C(=O)c3cc(F)ccc3OCC2C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.41
GPR119 Q8TDV5 2/20 0.40
HDAC6 Q9UBN7 2/20 0.39
CCNT1 O60563 4/20 0.39
CDK9 P50750 4/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
SMARCA2 P51531 1/20 0.37
SMARCA4 P51532 1/20 0.37
PBRM1 Q86U86 1/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
IDO2 Q6ZQW0 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
SCN9A Q15858 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411908 0.89 TP53 (0.46) USP30GPR119HDAC6TP53SMARCA2
SCHEMBL4412326 0.88 MAPT (0.41) USP30GPR119HDAC6TP53MAPT
SCHEMBL4419521 0.88 USP30 (0.41) USP30GPR119TP53SMARCA2SMARCA4
SCHEMBL4410957 0.88 FPR2 (0.42) USP30GPR119HDAC6TP53SMARCA2
SCHEMBL4411944 0.87 ALDH1A1 (0.43) USP30GPR119TP53
SCHEMBL24558178 0.86 USP30 (0.39) USP30GPR119HDAC6TP53MAPT
SCHEMBL4410911 0.86 GPR119 (0.39) USP30GPR119HDAC6TP53MAPT
SCHEMBL4408213 0.85 USP30 (0.43) USP30GPR119HDAC6TP53SMARCA2
SCHEMBL4410917 0.85 USP30 (0.49) USP30GPR119HDAC6SMARCA2SMARCA4
SCHEMBL14480601 0.85 P2RY14 (0.42) USP30GPR119HDAC6MAPTSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof HTR2C, HTR2A, HTR5A USP30 4369/4885GPR119 234/4885HDAC6 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.